Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
about
Harnessing the immune system to improve cancer therapyImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationThe evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysisAssociation of cytotoxic T-lymphocyte antigen 4 +49A/G gene polymorphism with acute rejection risk in renal transplantation.Molecular alterations in the TCR signaling pathway in patients with aplastic anemia.CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma.Molecular Imaging of Immunotherapy Targets in Cancer.Advances in immunotherapy for melanoma management.Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis.Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy.CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.Cancer immunotherapy: harnessing the immune system to battle cancer.ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer.Human T Cell Memory: A Dynamic ViewDiagnostic performance of CTLA-4, carcinoembryonic antigen and CYFRA 21-1 for malignant pleural effusion.Unintended Immunological Consequences of Biologic Therapy.Immunotherapy of colorectal cancer: new perspectives after a long path.Immune targets and neoantigens for cancer immunotherapy and precision medicine.Is immunotherapy here to stay in multiple myeloma?Signals that drive T follicular helper cell formation.Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities.Notch-mediated conversion of activated T cells into stem cell memory-like T cells for adoptive immunotherapy.Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award.The Clinicopathological and Prognostic Implications of FoxP3+ Regulatory T Cells in Patients with Colorectal Cancer: A Meta-Analysis.Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy.Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab.Monoclonal antibodies against cutaneous T-cell lymphomas.Paradigm Shift to Neuroimmunomodulation for Translational Neuroprotection in Stroke.A Case Report of Drug-Induced Myopathy Involving Extraocular Muscles after Combination Therapy with Tremelimumab and Durvalumab for Non-Small Cell Lung Cancer.Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma
P2860
Q26738698-FEE56616-51E8-4105-8C09-535D5C5C3FA2Q28068378-74DD5185-2BAE-46BA-9DF1-3915B6B518B4Q36192538-D8284872-168B-44A7-9888-322F34106EEEQ36319478-8716B807-381A-4782-8C61-49FEC056A82FQ36758322-6A17192C-45C4-40E6-B3CC-4814701150A9Q37079094-4B4FD51A-4CFA-4A94-BB4F-9BAC6553A316Q37309882-ED75C40D-E03D-4065-8F0C-001E9EFAE266Q37375978-C1850655-C9EF-478D-95D4-99196453B62AQ37392642-CA4A47FB-86F4-4B11-A785-05F3971A4BDDQ37619977-82342E59-F4CD-4A71-BBFA-0982DDEBF145Q38413093-FBB10A95-71DD-43FE-A937-A017A86DAA86Q38577828-CA80B402-8052-4EB1-B356-D1C31FB10B45Q38733611-33E654F4-4186-40DF-A3A0-6FB12D2D1B6FQ38761049-C031807B-0491-47B2-B76D-C2AF90BB2F02Q38785402-A2EBC51E-B122-4E17-BF5E-C759BEE1B3F6Q38871098-4782CE62-34E6-4E03-AAA2-51F7FA795DBCQ39043413-93E8A9F9-902E-4E0B-AC35-679AB4DA0DA1Q39057617-839F7647-9028-42C4-9D23-F65D59E8707AQ39084427-BE193308-74DC-48AE-8203-695C09EFAE98Q39382728-AB596EE8-9C8A-432B-8D9B-B74E8BA844FFQ39430042-7BB0DC32-B465-4A53-9874-AF5A0CFE2F87Q41993883-77300704-E6C7-4E8A-9A60-CD6534452F7CQ43218579-EF3B7335-0820-4709-AF70-2EA644B11823Q47101966-E472A296-46C2-4828-935F-581D456463F3Q48369113-002648B2-A3B4-4722-A1E8-ACBE0A58BA36Q51104725-857314BF-7FF7-4B5F-97DF-98766C80B51DQ51803389-14DE16C8-3894-4766-982E-7618EE2DF35CQ52564678-CF705F75-F93C-471C-B23A-01E1DB968FF9Q55390078-F6E199E7-C9B1-4618-B935-633AB54BDD06Q57132855-8AED98CB-BFD0-4F11-9FED-910332B32994
P2860
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
@en
type
label
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
@en
prefLabel
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
@en
P2860
P356
P1476
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
@en
P2093
Elizabeth Buchbinder
F Stephen Hodi
P2860
P304
P356
10.1172/JCI80012
P407
P577
2015-09-01T00:00:00Z